Ad
related to: medi cal manual of criteria for diabetes drug information sheet
Search results
Results from the WOW.Com Content Network
Medi-Cal was created in 1965 by the California Medical Assistance Program a few months after the national legislation was passed. [2] Approximately 15.28 million people were enrolled in Medi-Cal as of September 2022, [3] or about 40% of California's population; in most counties, more than half of eligible residents were enrolled as of 2020. [4]
With 13 million children and adults enrolled, Denti-Cal is the largest state-sponsored dental insurance program; Private contractor that administers Denti-Cal is Delta Dental. In 2016, the State of California awarded Delta Dental a new contract to provide administrative services for the Denti-Cal program, continuing the 42-year relationship [7]
There are different classes of hypoglycemic drugs, and selection of the appropriate agent depends on the nature of diabetes, age, and situation of the person, as well as other patient factors. Type 1 diabetes is a disease caused by the lack of insulin. Thus, insulin is the main treatment agent for type 1 and is typically administered via ...
A drug treatment for type 2 diabetes; belongs to a class of drugs called biguanides. First-line pharmacotherapy for type 2 diabetes mellitus. Mg/dL Milligrams per deciliter. How much glucose (sugar) is in a specific amount of blood. In self-monitoring of blood glucose, test results are given as the amount of glucose in milligrams per deciliter ...
Alogliptin, sold under the brand names Nesina and Vipidia, [2] [3] is an oral anti-diabetic drug in the DPP-4 inhibitor (gliptin) class. [4] Like other members of the gliptin class, it causes little or no weight gain, exhibits relatively little risk of hypoglycemia, and has relatively modest glucose-lowering activity. [1]
GLP-1 drugs for weight loss and type 2 diabetes include dulaglutide, liraglutide, and semaglutide. GIP/GLP-1s. These are dual-acting, meaning they target two receptors in the body: gastric ...
Self-injected drugs are especially difficult for people with vision or motor difficulties, which are common in people with type 2 diabetes. [29] Attempts to develop an orally bioavailable GLP-1 agonist, either a modified peptide, as in the case of oral semaglutide, [ 37 ] or a small molecule drug, have produced additional drug candidates. [ 28 ]
Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors.
Ad
related to: medi cal manual of criteria for diabetes drug information sheet